The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Frequent FGFR3 mutations in urothelial papilloma
Abstract
Activating point mutations in the FGFR3 gene occur frequently in low‐grade and low‐stage bladder carcinomas, whereas they are rare in high‐grade carcinomas. This study investigates the incidence of FGFR3 mutations in 12 urothelial papillomas and 79 pTaG1 tumours which were regraded according to the 1998 WHO/ISUP classification system, resulting in 62 papillary urothelial neoplasms of low malignant potential (PUNs‐LMP) and 17 low‐grade papillary urothelial carcinomas (LG‐PUCs). FGFR3 mutation analysis of 21 ovarian Brenner tumours was also performed. Seventy‐seven cases were detected with a mutation in the FGFR3 gene. The mutations were exclusively found in bladder neoplasms. In urothelial papilloma, generally considered a benign lesion, 9/12 (75%) mutations were found. This report is the first to describe a genetic defect in urothelial papilloma. A comparable percentage of mutations was found in PUNs‐LMP (85%) and LG‐PUCs (88%). No mutations were found in matched normal DNA from bladder tumour patients. The mean follow‐up was 5.78 years (range 0.21–17.60 years). Five patients developed high‐grade papillary urothelial carcinoma from 2.5 to 12 years after first diagnosis. Two patients died of bladder cancer. The mean number of recurrences (recurrence rate) per year was 0.03, 0.21, and 0.46, respectively, for papilloma, PUN‐LMP, and LG‐PUC. Urothelial papilloma is a rare lesion with a benign natural behaviour compared with PUN‐LMP and LG‐PUC of the bladder, but from a molecular perspective, papillomas should be classified together with all well‐differentiated urothelial neoplasms. Copyright © 2002 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Genetic alterations in bladder cancer
Dalbagni, G., Presti, J., Fair, W. R., Reuter, V., & Cordon-Cardo, C. (1993) · The Lancet · doi:10.1016/0140-6736(93)91595-d · Cited by 238
Cited by
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Fibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary
Montironi, R., & Lopez-Beltran, A. (2005) · International Journal of Surgical Pathology · doi:10.1177/106689690501300203 · Cited by 278
Self-citationAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Mechanism of FGF receptor dimerization and activation
Sarabipour, S., & Hristova, K. (2016) · Nature Communications · doi:10.1038/ncomms10262 · Cited by 255
Metadata
- Authors
- van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C., & van der Kwast, T. H.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2002-09-17
- Volume
- 198
- Issue
- 2
- Pages
- 245-251
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2144747113
- Cited by
- 189
- References
- 2
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.